Abstract Search

ey0018.9-1 | Cancer treatment and the risk of second neoplasia | ESPEYB18

9.1. Risk factors of subsequent central nervous system tumors after childhood and adolescent cancers: findings from the french childhood cancer survivor study

NMY Journy , WS Zrafi , S Bolle , B Fresneau , C Alapetite , RS Allodji , D Berchery , N Haddy , I Kobayashi , M Labbe , H Pacquement , C Pluchart , B Schwartz , V Souchard , C Thomas-Teinturier , C Veres , G Vu-Bezin , I Diallo , F de Vathaire

Cancer Epidemiol Biomarkers Prev. 2021; 30: 133141. https://pubmed.ncbi.nlm.nih.gov/33033142/This retrospective study of 152 patients and 604 matched-controls within the FCCSS (French Childhood Cancer Survivor Study) cohort aimed to identify clinical and therapeutic factors associated with long-term risk of subsequent primary neoplasm (SPN) in the central nervous system (CNS), occurri...

0 shares

ey0021.1-13 | New Treatments and Hopes | ESPEYB21

1.13. Long-term weight gain in children with craniopharyngioma

S Rovani , V Butler , D Samara-Boustani , G Pinto , L Gonzalez-Briceno , Quoc A Nguyen , G Vermillac , A Stoupa , A Besancon , J Beltrand , C Thalassinos , I Flechtner , Y Dassa , M Viaud , MB Arrom-Branas , N Boddaert , S Puget , T Blauwblomme , C Alapetite , S Bolle , F Doz , J Grill , C Dufour , F Bourdeaut , S Abbou , L Guerrini-Rousseau , A Leruste , K Beccaria , M Polak , D Kariyawasam

Brief Summary: This single-centre retrospective cohort study offers valuable insights into the trajectory of weight gain in a paediatric craniopharyngioma cohort over a mean follow-up period of 10.4 years, reinforcing the necessity for targeted interventions to address this issue.Craniopharyngioma poses a substantial clinical challenge in paediatric patients, primarily due to the risk of hypothalamic involvement. A particularly severe long-term consequen...

0 shares

ey0021.9-13 | Growth Problems in Cancer Survivors | ESPEYB21

9.13. GH and childhood-onset craniopharyngioma: when to initiate GH replacement therapy?

A Nguyen Quoc , K Beccaria , Briceno L Gonzalez , G Pinto , D Samara-Boustani , A Stoupa , J Beltrand , A Besancon , C Thalassinos , S Puget , T Blauwblomme , C Alapetite , S Bolle , F Doz , J Grill , C Dufour , F Bourdeaut , S Abbou , L Guerrini-Rousseau , A Leruste , S Brabant , I Cavadias , M Viaud , N Boddaert , M Polak , D Kariyawasam

Brief Summary: This retrospective, observational, single centre study compared the risk of tumor progression or recurrence in 71 patients with childhood-onset craniopharyngioma (CP) who started GH replacement therapy (GHRT) with different latency from the end of tumor treatment.GHRT latency was defined as the time from end of CP treatment (last debulking procedure or radiotherapy, or from CP diagnosis for the 5 patients without any debulking procedure or...

0 shares

ESPE Yearbook of Paediatric Endocrinology

9.1. Risk factors of subsequent central nervous system tumors after childhood and adolescent cancers: findings from the french childhood cancer survivor study

1.13. Long-term weight gain in children with craniopharyngioma

9.13. GH and childhood-onset craniopharyngioma: when to initiate GH replacement therapy?

BiosciAbstracts